Cite

HARVARD Citation

    Muro, K. et al. (n.d.). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet oncology. 17 (6), pp. 717-726. [Online]. 
  
Back to record